Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.

NCT05785208 is registered in ClinicalTrials.gov with Fondazione Policlinico Universitario Agostino Gemelli IRCCS as lead sponsor.

NCT NCT05785208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05785208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy Study of Osimertinib in Treatment-naïve Patients With EGFR Mutant NSCLC According to TP53 Mutational Status.
Lead sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase
Phase 4
Overall status
Unknown status
Start date
June 28, 2022
Completion date
October 31, 2025
Enrollment
122 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer